Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more
Vir Biotechnology Inc (VIR) - Net Assets
Latest net assets as of December 2025: $765.28 Million USD
Based on the latest financial reports, Vir Biotechnology Inc (VIR) has net assets worth $765.28 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.00 Billion) and total liabilities ($237.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $765.28 Million |
| % of Total Assets | 76.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | -46.55% |
| 10-Year Change | N/A |
| Growth Volatility | 52.29 |
Vir Biotechnology Inc - Net Assets Trend (2017–2025)
This chart illustrates how Vir Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vir Biotechnology Inc (2017–2025)
The table below shows the annual net assets of Vir Biotechnology Inc from 2017 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $765.28 Million | -33.48% |
| 2024-12-31 | $1.15 Billion | -27.66% |
| 2023-12-31 | $1.59 Billion | -23.47% |
| 2022-12-31 | $2.08 Billion | +45.12% |
| 2021-12-31 | $1.43 Billion | +99.74% |
| 2020-12-31 | $716.85 Million | +69.09% |
| 2019-12-31 | $423.94 Million | +336.61% |
| 2018-12-31 | $-179.18 Million | -159.99% |
| 2017-12-31 | $-68.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vir Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 111981900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $14.00K | 0.00% |
| Other Comprehensive Income | $-2.06 Million | -0.27% |
| Other Components | $1.97 Billion | 256.78% |
| Total Equity | $765.28 Million | 100.00% |
Vir Biotechnology Inc Competitors by Market Cap
The table below lists competitors of Vir Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TripAdvisor Inc
NASDAQ:TRIP
|
$974.07 Million |
|
Trigano S.A
OTCGREY:TGNOF
|
$975.07 Million |
|
Corporacion Financiera Alba SA
MC:ALB
|
$975.79 Million |
|
SiteMinder Limited
PINK:SDRMF
|
$976.42 Million |
|
VIZIO HLDG.CL.A DL-0001
F:7UF
|
$973.76 Million |
|
Jafron Biomedical Co Ltd
SHE:300529
|
$973.63 Million |
|
Allied Properties Real Estate Investment Trust
PINK:APYRF
|
$973.59 Million |
|
PT VKTR Teknologi Mobilitas
JK:VKTR
|
$973.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vir Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,150,385,000 to 765,276,000, a change of -385,109,000 (-33.5%).
- Net loss of 437,987,000 reduced equity.
- Other comprehensive income decreased equity by 340,000.
- Other factors increased equity by 53,218,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-437.99 Million | -57.23% |
| Other Comprehensive Income | $-340.00K | -0.04% |
| Other Changes | $53.22 Million | +6.95% |
| Total Change | $- | -33.48% |
Book Value vs Market Value Analysis
This analysis compares Vir Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.72x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-9.88 | $9.48 | x |
| 2018-12-31 | $-1.85 | $9.48 | x |
| 2019-12-31 | $3.94 | $9.48 | x |
| 2020-12-31 | $6.02 | $9.48 | x |
| 2021-12-31 | $10.73 | $9.48 | x |
| 2022-12-31 | $15.41 | $9.48 | x |
| 2023-12-31 | $11.86 | $9.48 | x |
| 2024-12-31 | $8.44 | $9.48 | x |
| 2025-12-31 | $5.52 | $9.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vir Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.23%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -638.87%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.31x
- Recent ROE (-57.23%) is below the historical average (-18.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -46880.54% | 0.00x | 0.00x | $-62.96 Million |
| 2018 | 0.00% | -13350.69% | 0.00x | 0.00x | $-97.97 Million |
| 2019 | -41.20% | -24568.64% | 0.00x | 1.21x | $-217.08 Million |
| 2020 | -41.66% | -391.09% | 0.08x | 1.28x | $-370.35 Million |
| 2021 | 36.92% | 48.25% | 0.56x | 1.36x | $385.40 Million |
| 2022 | 24.82% | 31.92% | 0.58x | 1.35x | $308.04 Million |
| 2023 | -38.68% | -713.69% | 0.04x | 1.21x | $-774.08 Million |
| 2024 | -45.37% | -703.40% | 0.05x | 1.22x | $-637.00 Million |
| 2025 | -57.23% | -638.87% | 0.07x | 1.31x | $-514.51 Million |
Industry Comparison
This section compares Vir Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vir Biotechnology Inc (VIR) | $765.28 Million | 0.00% | 0.31x | $973.78 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |